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Abstract
Objectives Pleuroparenchymal fibroelastosis (PPFE) is a rare
idiopathic interstitial pneumonia (IIP) with variable clinical
and radiological features. Diagnosis is based on histology ob-
tained by surgical lung biopsy, which is associated with sig-
nificant mortality and morbidity. This study aims to briefly
review PPFE and discuss the role of CT-guided transthoracic
core lung biopsy (TTB) in its diagnosis.
Materials/Methods Four cases of PPFE diagnosed at our in-
stitution with TTB are reported and discussed.
Results Clinical, radiological and histological features are in
agreement with the previous literature cases. TTB provided
the diagnosis in all cases. Iatrogenic pneumothorax was the
main complication in all patients. Placement of a chest tube
was needed in three patients. An overlap between PPFE and
other interstitial lung diseases (ILD) was documented.
Conclusion PPFE is an underdiagnosed IIP, so radiologist
awareness of it needs to bewidespread in patients with fibrosis
with apical-caudal distribution. Coexistence of different lung
diseases strengthens the idea of a predisposing factor. TTB
proved to be a good diagnostic tool and can be considered
the first choice for invasive assessment of these patients.
PFFE has a variable course with no established therapeutic
options; therefore a multidisciplinary team is crucial in the
approach to patients with ILD.
Main messages/Teaching Points
• PPFE should be considered in the differential diagnosis of
fibrosis with apical-caudal distribution.
• CT-guided TTB can be considered the first choice for inva-
sive assessment of PPFE.
• Site of biopsy has to be chosen carefully in order not to miss
PPFE.
• Coexistence of different lung diseases strengthens the idea of
a predisposing factor.
• A multidisciplinary team is crucial in the approach to pa-
tients with ILD.
Keywords Idiopathic interstitial pneumonia . Computed
tomography . Biopsy . Lung . Fibrosis
Introduction
Pleuroparenchymal fibroelastosis (PPFE) is a rare idiopathic
interstitial pneumonia (IIP) first described as idiopathic pul-
monary upper lobe fibrosis in 1992 in the Japanese literature
by Aminati et al. [1] and with approximately 70 patients de-
scribed in the English-language literature until now [1–11].
This entity is characterised by fibrotic and elastotic thickening
of the pleura and subpleural lung parenchyma, mainly in the
upper lobes [4]. Although the aetiology of PPFE is considered
idiopathic in most cases, an association with a wide range of
factors has been reported such as genetic predisposition; re-
current lower respiratory tract infections; underlying diseases
or conditions such as collagen vascular diseases, bone-
marrow transplantation or lung transplant patients suffering
from restrictive allograft syndrome [5–8]. The therapeutic ap-
proach is highly variable in the published clinical cases with
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no clearly definitive therapeutic options other than lung trans-
plantation [9]. Disease progression occurs in 60 % of patients
with death from disease in 40 % [10]. The largest series
of patients reported showed that of ten patients, five
died during the first 2 years of evolution [1–11].
Nevertheless, no specific data related with survival is
defined, but an overall bad prognosis can be assumed
based on available data.
In all the published literature case series of PPFE the diag-
nosis was made by surgical lung biopsy [1–11]. However, the
role of surgical biopsy in the diagnosis of IIP is still contro-
versial because it can be associated with significant mortality
and morbidity [12–15] with previous reports showing mortal-
ity rates between 0 and 17 % and a morbidity rate of 13 %
[12]. On the other hand, Manhire et al. documented only a
0.15 % mortality rate with CT-guided transthoracic lung biop-
sy (TTB) [16] while some articles report an aetiological diag-
nosis in 79 to 100 % of the cases of interstitial lung diseases
(ILDs) obtained by TTB [17–20].
The aim of this article is to review the clinical and imaging
findings with pathological correlation of PPFE and to discuss
the role of CT-guided transthoracic core lung biopsy (TTB) in
the diagnosis of PPFE.
Materials and methods
Four patients with PPFE underwent imaging evaluation
at our institution between 2011 and 2014. High-
resolution computer tomography (HRCT) was performed
in all the patients. The medical records and radiology
reports of all patients were reviewed and discussed in
the Multidisciplinary Interstitial Lung Disease Board
(MILDB) pe r fo rmed week ly (wh i ch inc lude s
pulmonologists, thoracic radiologists and pathologists).
Each patient was posteriorly submitted to TTB in a
dual-slice spiral CT scanner (Siemens Somatom®
Emotion Duo) with fluoroscopy. An automatic core bi-
opsy system (Bard® Magnum®) with an 18-gauge cut-
ting needle (variable length, depending on the disease’s
depth) was used in all patients. All the patients had
local anaesthesia with 10 cc lidocaine hydrochloride
2 %. The biopsy was performed in the area of greater
pleuroparenchymal thickness and the needle was placed
outside the visceral/parietal pleura before performing the
biopsy. Only one core biopsy was made in all patients.
The samples obtained were preserved in a 10 % form-
aldehyde solution. A chest radiogram was posteriorly
performed to evaluate complications. Histological sam-
ples were analysed and interpreted by two different pul-
monary pathologists who agreed on the diagnosis in all
cases.
Results
Clinical, laboratory and pulmonary tests features
(Table 1)
All patients were females aged between 59 and 67 at
presentation. Patient 4 had a history of smoking and
patient 2 had a history of pulmonary tuberculosis,
post-infectious bronchiectasis and recurrent respiratory
infections. Patients 3 and 4 had occupational inhalation
exposure: patient 3 has current environmental inhalation
exposure (birds) and familiar history of interstitial lung
disease (mother died of idiopathic pulmonary fibrosis);
patient 4 had a previous diagnosis of chronic hypersen-
sitivity pneumonitis.
At presentation all patients complained of dyspnoea on
exert ion with progressive worsening and cough.
Bronchoalveolar lavage and bronchoscopy indicated no ab-
normalities and bronchial biopsies showed no evidence of
malignancy, granulomas or other diagnoses.
Lung function tests showed a mild restrictive ventila-
tory impairment (CVF 74.23 ± 13.5) and mild decrease of
diffusion capacity (DLCO 53.1 ± 17.05). All patients
demonstrated oxygen desaturation in the 6-min walking test.
Bronchoalveolar lavage was performed in three patients.
Two of them had neutrophilia and eosinophilia, and the
other had lymphocytosis and eosinophilia.
Imaging and biopsy findings
HRCT images show dense pleural and subpleural consolidation
with a reticular pattern, predominantly in the upper lobes. The
upper lobes were always more severely involved, with involve-
ment of the lower lobes being absent or less marked (apical-
caudal distribution). Associated features included upper lobe
volume loss, architectural distortion and traction bronchiectasis
(Figs. 1, 2, 3 and 4). One of the patients showed significant
worsening relative to previous examinations (Fig. 2).
Two of the patients showed reticular opacities with some
areas of honeycombing and traction bronchiectasis (Figs. 1, 2
and 3). The other patient had co-existent cystic bronchiectasis
(Fig. 5). The patients underwent a TTB in the higher density
zones (Fig. 6). All the patients were complicated with mild to
moderate iatrogenic pneumothoraxes. Placement of a chest
tube was needed in three patients. The pneumothorax resolved
completely before discharge with a hospital stay ranging
between 1 day and 17 days. One of the patients was also
complicated with subcutaneous emphysema.
Pathological findings
Histological evaluation showed, in all four cases, pleural
and subpleural fibrosis with an abrupt transition to
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normal lung parenchyma. The elastic stains demonstrate
deposition of dense elastic fibers (elastosis) in the
subpleural fibrotic lung lesion and alveolar walls
confirming the diagnosis (Fig. 7).
Follow-up
Only one of the patients clinically and functionally worsened
after 20 months of follow-up and died because of nosocomial
Fig. 1 Axial high-resolution
chest tomography (HRCT)
images (a–c) and coronal
reformatted images (d) of patient
1 show pleural and subpleural
thickening with severe fibrotic
changes in the marginal
parenchyma with apical-caudal
distribution. Some areas of
traction honeycombing are also
seen
Fig. 2 Axial high-resolution
chest tomography (HRCT)
images in 2007 (a–c) and 2012
(d–f) of patient 2 show pleural
and subpleural thickening with
severe fibrotic changes in the
marginal parenchyma with
apical-caudal distribution. Some
areas of traction bronchiectasis
and honeycombing are also seen.
Note the evolution between 2007
and 2012 (at the diagnosis)
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pneumonia after a surgery for hiatal hernia correction (patient
1). The other patients have been clinically and functionally
stable until now.
Discussion
PPFE is a rare, underdiagnosed and increasingly recognised
disorder with unique clinical, radiological and pathological
features [1–11, 21]. It has been defined as a distinct IIP entity
in the English literature by Frankel et al. [5] and was recently
included in the International Multidisciplinary Classification
of the Idiopathic Interstitial Pneumonias of the American
Thoracic Society/European Respiratory Society in the catego-
ry of rare IIP [9].
Given its rarity in addition to the fact that it is a very re-
cently recognised entity, with fewer than a hundred cases de-
scribed until now, there are no reliable data on the incidence
and prevalence [1–11].
PPFE also has a distinct therapeutic approach and progno-
sis in comparison to other IIPs; therefore an accurate diagnosis
is important. Although there are no specific therapeutics with
proven efficacy, the majority of patients described had been
treated with immunosuppressant therapy and a minority
Fig. 3 Axial high-resolution
chest tomography (HRCT)
images (a–c) and coronal
reformatted images (d) of patient
3 show pleural and subpleural
thickening with moderate fibrotic
changes in the marginal
parenchyma with apical-caudal
distribution. Some areas of
honeycombing are also seen
Fig. 4 Axial high-resolution
chest tomography (HRCT)
images (a–d) of patient 4 show
pleural and subpleural thickening
with moderate fibrotic changes in
the marginal parenchyma with
apical-caudal distribution. These
features are more evident in the
right lobe. Note also, in c, a slight
Btree-in-bud^ pattern in the
middle lobe compatible with
concomitant pulmonary infection
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associated with recurrent infections with plaquinol. This is
significantly different from other IIPs such as idiopathic pul-
monary fibrosis treated with antifibrotics such as pirfenidone
or nintedanib or others with a predominant inflammatory
component treated mainly with corticoids [1–11].
In the majority of the patients reported in the literature the
clinical course was progressive, despite aggressive treatment.
The survival however is variable, ranging from 4 months to
7 years following diagnosis, with half of the patients dying in
the first 2 years. Therefore, early diagnosis is essential [1–11].
PPFE presents in adults with a median age of 57 years with
no sex predilection and occurs most commonly in patients
with absence of smoking habits [12]. In our data the patients
were older (median age of 62.5 years) and all were female.
Three patients were non-smokers, being in line with previous
studies. Concerning the aetiology, our data are also in agree-
ment with published cases with one of the patients having a
history of recurrent respiratory infections and other familiar
history of IIP [12].
There is also a certain variability of clinical presentation
and the symptoms are often nonspecific with the most
common presentation symptoms published being shortness
of breath and cough, also in line with our cases [1–12].
HRCT findings in all cases were in agreement with the previ-
ously described series and the histopathological features ob-
tained by TTB were considered representative and compatible
with the diagnosis of PPFE after a multidisciplinary
discussion.
The most common complication with TTB is pneumotho-
rax, which occurs in 0–61 % of lung biopsies. Although rare,
other complications include pulmonary haemorrhage, haemo-
thorax, gas embolism and cardiorespiratory arrest [16, 20]. In
the case series of PPFE, the published patients were submitted
to surgical lung biopsy [1–12] with a reported death of one
patient following surgical lung biopsy complicated by large
bronchopleural fistulae [11]. Becker et al. also postulated that
these patients might be prone to the development of secondary
spontaneous pneumothoraxes [11]. In our study the diagnosis
of PPFE was made by TTB in all patients. Although all pa-
tients had pneumothoraxes, they resolved before discharge
with only one patient needing hospitalisation for more than
1 week. This patient needed two biopsies, was the first
Fig. 5 Axial HRCT scans in
2007 (a–b) and 2012 (c–d) in
patient 2 show multiple cystic
bronchiectasis in the middle right
lobe and lingula with worsening
between 2007 and 2012
Fig. 6 Ancillary image of a
CT-guided transthoracic core lung
biopsy. TTB at the upper left lobe
in patient 1 (a) and TTB in patient
3 at the upper right lobe (b)
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diagnosed at our institution and had the worst prognosis, dy-
ing 20 months after diagnosis. Therefore, TTB can be consid-
ered the first choice for the invasive assessment of PPFE,
sparing patients a late surgical lung biopsy. However, we only
had four patients, and more reports are needed to improve the
reliability.
Chronic hypersensitivity pneumonitis and apical caps
are differential diagnoses to consider when there is pre-
dominant involvement of the upper lobes, and they can
have radiological and histological features that overlap
with those of PPFE. The latter is particularly challenging,
especially when associated with tuberculosis scars, which,
in our country, have a medium incidence. Apical caps also
tend to occur in older cigarette smokers and are localised
in the upper lobes, usually with no extension to other
lobes. In these patients centrilobular emphysema can be
seen and they are typically asymptomatic with nonprogres-
sive disease [4, 5]. On the other hand, PPFE has a more
diffuse subpleural distribution and can also affect basal
portions and other lobes [4, 5]. In the case of hypersensi-
tivity pneumonitis like Piciucchi et al. described, lesions
have a bronchiolar location and do not have a subpleural
and pleural predominance like in PPFE [4]. In our study
one patient had a history of previous tuberculosis and two
other environmental exposures, making the diagnosis more
challenging. One of them even had a misdiagnosis of
chronic hypersensitivity pneumonitis. Therefore, PPFE
must be considered in the differential diagnosis of these
entities to alert pathologists to perform elastic fibre stains,
making the diagnosis easier.
Reddy et al. also describe a high prevalence of coexistent
ILDs, such as nonspecific interstitial pneumonia (NSIP) and
usual interstitial pneumonia (UIP). They describe a pattern of
ILD in 5 of 12 patients with PPFE and bronchiectasis in 1 of
the patients. The features of coexistent fibrosis, including UIP,
have been described more extensively in the Japanese litera-
ture [7]. Our study, like in previous reports, shows that three
patients had other concomitant pleuroparenchymal changes
supporting the previously postulated concept that these pa-
tients might have a predisposition to lung diseases, which
may manifest as different histopathological patterns of fibrosis
[7]. Therefore, the location of the TTB needs to be carefully
selected according to the HRCT to collect biopsies of PPFE
and not from the coexistent lung disease.
Regarding follow-up, there are no guidelines related to
PPFE follow-up, namely in a particular situation where a
definitive diagnosis is not possible. However it is reason-
able to propose lung function tests every 3–6 months, a
thoracic x-ray every 6 months and a thoracic HRCT scan
every 12 months. A close follow-up should be carried out
for patients with a family history of PPFE who tend to
have a more aggressive disease course and should have a
close follow-up [3].
In conclusion, PPFE is an underdiagnosed disease,
with uncertain prevalence and incidence. Thus, radiolo-
gists’ awareness of the condition needs to be wide-
spread and routinely considered in patients with fibrosis
with apical-caudal distribution to alert the pathologist to
perform elastic fibre stains, making the diagnosis easier.
The fact that a number of patients with PPFE demon-
strated features of coexistent lung disease should also
alert radiologists to consider both diffuse forms of
PPFE and other lung diseases in the differential diagno-
sis. TTB has been shown to be a good diagnostic tool
and can be considered the first choice for the invasive
assessment of PPFE, sparing patients a late surgical
lung biopsy. The biopsy site has to be chosen carefully
according to the HRCT in order not to miss PPFE be-
cause of other lung diseases. This disease has a variable
course with survival rates ranging from months to years,
with no defined therapeutic options. Therefore, a
Multidisciplinary Interstitial Lung Disease Board is cru-
cial to the early diagnosis of PPFE as well as to estab-
lishing an adequate approach in patients with ILD.
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Fig. 7 a Thickened visceral pleura and prominent subpleural fibrosis
characterised by abnormal increase of elastic tissue and dense collagen
(H&E, 100×). Abrupt transition to normal parenchyma is also seen.
Parenchyma distant from the pleura is spared. b Elastosis of the
alveolar walls (black arrow; orcein, 100×.) with a predominant intra-
alveolar fibrosis (white arrow)
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